MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
Biota Pharmaceuticals (NASDAQ:BOTA)
Organization & Developments: Biota
Parents
Biota Pharmaceuticals (NASDAQ:BOTA)
Children
2015: The company additionally has royalty streams from Relenza and Inavir that help to lessen cash burn.
2015: The company is led by a CEO in Joe Patti that help take a company in Inhibitex from founding to a multi-billion dollar sale to Bristol-Myers Squibb (NYSE:BMY).
2015: With Phase 2 readouts from three exciting programs in 2016 and $66.3 million in cash/equivalents at Q3 end, Biota presents a unique value proposition to investors.
Biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.
Developing treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the BARDA that is designed to provide up to $231 million in financial support to complete its clinical dev
Jumps
*Key People: Biota
Finance & Acquisition: Biota